Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2024-10-21 Report Publication Anno…
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Responsibility statement for first half year of 2024
Report Publication Announcement Classification · 98% confidence The document text is extremely short (492 characters) and explicitly states, 'Please find attached the first half 2024 financial report including the Responsibility Statement.' This structure—a brief announcement pointing to an attached or linked report—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is not the comprehensive Interim Report (IR) itself, but the announcement of its publication. The reference to 'first half 2024' confirms it relates to an interim period.
2024-10-21 English
Vistin Pharma ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a specific transaction: the purchase of shares in Vistin Pharma ASA by an entity closely associated with a board member of Saga Pure ASA. This structure and content directly correspond to insider trading reports or director's dealing disclosures, which are mandated filings in many jurisdictions. Based on the provided definitions, this aligns perfectly with 'Director's Dealing' (DIRS). The document is not an annual report, earnings release, or a general announcement of a report.
2024-09-26 English
Vistin Pharma ASA: Mandatory notification of trade
Major Shareholding Notification Classification · 99% confidence The document explicitly states 'Mandatory notification of trade' and details a purchase of shares by an associated party (Saga Pure ASA, associated with board member Øystein Stray Spetalen). This directly corresponds to the definition of reporting personal share transactions by company directors and executives (insider trades). The relevant code is DIRS (Director's Dealing). The document length is very short (542 chars), but the content is a direct notification of a transaction, not an announcement of a report, making DIRS the correct classification over RPA or RNS.
2024-09-26 English
Disclosure of large shareholding and mandatory notification of trade in Vistin Pharma ASA
Director's Dealing Classification · 100% confidence The document is a structured template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a specific transaction: the purchase of shares in Vistin Pharma ASA by an entity closely associated with a board member of Saga Pure ASA. This format and content directly correspond to regulatory filings concerning insider trading or director's dealings. Reviewing the definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification for reports of personal share transactions by company directors and executives (insider trades). The document is not a general announcement (RPA/RNS) but the actual disclosure form.
2024-09-13 English
Disclosure of large shareholding and mandatory notification of trade in Vistin Pharma ASA
Major Shareholding Notification Classification · 99% confidence The document explicitly details a mandatory notification regarding a trade in shares by an associated party (Saga Pure ASA and board member Øystein Stray Spetalen) in Vistin Pharma ASA. This involves reporting changes in share ownership that cross specific thresholds or involve insiders/closely associated parties. This aligns directly with the definition of 'Director's Dealing' (DIRS) or 'Major Shareholding Notification' (MRQ). Since the text focuses on the transaction by an associated party of a board member and the resulting ownership percentage (5.02%), it strongly suggests an insider transaction disclosure, which falls under DIRS. If it were purely about a large shareholder crossing a threshold without the insider link, MRQ might apply, but the mention of the board member makes DIRS the most precise fit for reporting executive/director-related trades.
2024-09-13 English
Vistin Pharma ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is a structured template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a 'Purchase of shares' transaction by an individual closely associated with a board member of Saga Pure ASA, involving shares of Vistin Pharma ASA. This format and content directly correspond to regulatory filings concerning insider trading or transactions by management/directors. Among the provided codes, 'Director's Dealing' (DIRS) is the most appropriate classification for reports detailing personal share transactions by company directors and executives or their close associates.
2024-08-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.